Goodwill and Other Intangible Assets - Finite-lived and Indefinite-lived Intangible Assets (Detail) (USD $) In Millions, unless otherwise specified	Jun. 29, 2014		Dec. 31, 2013
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets, Gross Carrying Amount	$ 74,895		$ 74,677
Finite-lived Intangible Assets, Accumulated Amortization	(45,238)	[1]	(43,119)	[1]
Finite-lived Intangible Assets, less Accumulated Amortization	29,657		31,558
Total indefinite-lived intangible assets	7,703		7,827
Intangible assets, gross carrying amount	82,598	[1]	82,504	[1]
Identifiable Intangible Assets, less Accumulated Amortization	37,360	[1]	39,385	[1]
Brands and Other [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets	7,374		7,384
Brands and Other [Member] | Global Innovative Pharmaceutical [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
Brands and Other [Member] | Global Vaccines, Oncology and Consumer Healthcare [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	69.00%
Brands and Other [Member] | Global Established Pharmaceutical [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	31.00%
Brands and Other [Member] | Worldwide Research and Development Expense [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%	[2]
In Process Research and Development [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets	329		443
In Process Research and Development [Member] | Global Innovative Pharmaceutical [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	9.00%
In Process Research and Development [Member] | Global Vaccines, Oncology and Consumer Healthcare [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	58.00%
In Process Research and Development [Member] | Global Established Pharmaceutical [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	9.00%
In Process Research and Development [Member] | Worldwide Research and Development Expense [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	24.00%	[2]
Developed Technology Rights [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets, Gross Carrying Amount	72,030		72,038
Finite-lived Intangible Assets, Accumulated Amortization	(43,599)		(41,541)
Finite-lived Intangible Assets, less Accumulated Amortization	28,431		30,497
Developed Technology Rights [Member] | Global Innovative Pharmaceutical [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	34.00%
Developed Technology Rights [Member] | Global Vaccines, Oncology and Consumer Healthcare [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	32.00%
Developed Technology Rights [Member] | Global Established Pharmaceutical [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	34.00%
Developed Technology Rights [Member] | Worldwide Research and Development Expense [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%	[2]
Brands and Other [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets, Gross Carrying Amount	1,944		1,743
Finite-lived Intangible Assets, Accumulated Amortization	(815)		(773)
Finite-lived Intangible Assets, less Accumulated Amortization	1,129		970
Brands and Other [Member] | Global Innovative Pharmaceutical [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
Brands and Other [Member] | Global Vaccines, Oncology and Consumer Healthcare [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	80.00%
Brands and Other [Member] | Global Established Pharmaceutical [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	20.00%
Brands and Other [Member] | Worldwide Research and Development Expense [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%	[2]
License Agreements and Other [Member]
Finite Lived and Indefinite Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets, Gross Carrying Amount	921		896
Finite-lived Intangible Assets, Accumulated Amortization	(824)		(805)
Finite-lived Intangible Assets, less Accumulated Amortization	$ 97		$ 91

[1] The decrease in identifiable intangible assets, less accumulated amortization, is primarily related to amortization and, to a much lesser extent, asset impairment charges, partially offset by the Nexium over-the-counter milestone. For information about impairments of intangible assets, see Note 4. Other (Income)/Deductions—Net. For information about the Nexium over-the-counter milestone, see Note 2A. Acquisition, Divestiture, Collaborative Arrangement and Equity-Method Investments: Acquisition.

[2] Worldwide Research and Development.